-
Company Insights
Innovation and Patenting activity of Shin Nippon Biomedical Laboratories Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Shin Nippon Biomedical Laboratories Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Company Insights
Innovation and Patenting activity of Shin Nippon Air Technologies Co., Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Shin Nippon Air Technologies Co., Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
Arteriosclerosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Arteriosclerosis - Drugs In Development, 2023’, provides an overview of the Arteriosclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arteriosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Thrombosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Thrombosis - Drugs In Development, 2023’, provides an overview of the Thrombosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Nobeoka MSW Power Plant
Nobeoka MSW Power Plant is a biopower project located in Miyazaki, Japan. The project was developed by Shin Nippon Machinery Co Ltd. The project came online in 2007. Empower your strategies with our Nobeoka MSW Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Product Insights
Inhalers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Inhalers Pipeline Market Report Overview Inhalers deliver medication to the lungs. The inhalers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segment ·       Dry Powder Inhaler Devices Key Territories ·       The US ·       Europe ·       Australia...
-
Product Insights
Dry Powder Inhaler Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Dry Powder Inhaler Devices Pipeline Market Report Overview Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. The Dry Powder Inhaler Devices pipeline market research report provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that are in progress. Key Territories ·       The US ·       China ·       Europe ·       Global ·       Australia Key...
-
Thematic Analysis
Batteries – Thematic Intelligence
Explore the following trends and insights from the ‘Batteries’ thematic report: Synopsis of the batteries theme and understand its progress over the past decade. Key trends impacting the growth of the theme over the next 12 to 24 months, namely, technology trends, macroeconomic trends, and regulatory trends. Multiple data sets, including patents and M&A trends, to set smart business goals. The report also provides a timeline highlighting milestones in the development of the batteries. Core segments of the value chain, including...
-
Product Insights
Transmucosal Drug Delivery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Transmucosal Drug Delivery Pipeline Market Report Overview A Transmucosal drug delivery device is intended for the localized delivery of medications through a mucous membrane. The transmucosal drug delivery pipeline market research report provides comprehensive information about the transmucosal drug delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segment ·      Nasal ·      Vaginal ·      Buccal Delivery ·      Rectal Key Territories ·      The US...
-
Company Profile
NewSatsuma Pharmaceuticals Inc – Company Profile
Satsuma Pharmaceuticals Inc (Satsuma), a subsidiary of Shin Nippon Biomedical Laboratories Ltd, is a biopharmaceutical company that develops novel therapeutic products for the acute treatment of migraine. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to be self-administered with a pre-filled, single-use, nasal delivery device. Satsuma is headquartered in South San Francisco, California,...
Add to Basket